And if we had anything close to a decent stroke association we would have a defined plan on how to accomplish reducing stroke disability and could get the NIH to fund that plan. With no plan, no funding. But the stupidity reigns.
http://www.nia.nih.gov/newsroom/2013/09/nih-funding-boosts-new-alzheimers-research-prevention-novel-drug-targets
Researchers
will test promising drugs aimed at preventing Alzheimer’s and identify
and validate biological targets for novel therapies, with approximately
$45 million in new funding from the National Institutes of Health. The
initiative will support innovative new studies as part of an intensified
national effort to find effective interventions for this devastating
degenerative brain disease.
The studies are among the first to be developed with direction from the 2012 NIH Alzheimer’s Disease Research Summit: Path to Treatment and Prevention and reflect research goals in the National Plan to Address Alzheimer’s Disease. Of the funding, $40 million is from an allocation from the Office of the NIH Director, Dr. Francis Collins, with additional funding from the National Institute on Aging (NIA), the lead Institute within NIH for Alzheimer’s research.
“As many as 5 million Americans face the challenge of Alzheimer’s disease, which robs them of their memories, their independence, and ultimately, their lives,” Dr. Collins said. “We are determined, even in a time of constrained fiscal resources, to capitalize on exciting scientific opportunities to advance understanding of Alzheimer’s biology and find effective therapies as quickly as possible.”
The clinical trials investigate possible ways to stop the progression of the disease. The translational research study awards are focused on identifying, characterizing and validating novel therapeutic targets.
“We know that Alzheimer’s-related brain changes take place years, even decades, before symptoms appear. That really may be the optimal window for drugs that delay progression or prevent the disease altogether,” said NIA Director Dr. Richard Hodes. “The clinical trials getting under way with these funds will test treatments in symptom-free volunteers at risk for the disease, or those in the very earliest stages—where we hope we can make the biggest difference.”
Basic and genetic studies of the disease—from the abnormal proteins involved, to genetic influences, to inflammation and other Alzheimer’s-related brain changes—have advanced our knowledge. This has given us new insights into the biological underpinnings of this extremely complex disorder, Dr. Hodes said.
Today’s awards support the following clinical trials. (Individual investigators can be contacted about when these studies will recruit participants.):
- See more at: http://www.nia.nih.gov/newsroom/2013/09/nih-funding-boosts-new-alzheimers-research-prevention-novel-drug-targets#sthash.LdFTJjkC.dpuf
The studies are among the first to be developed with direction from the 2012 NIH Alzheimer’s Disease Research Summit: Path to Treatment and Prevention and reflect research goals in the National Plan to Address Alzheimer’s Disease. Of the funding, $40 million is from an allocation from the Office of the NIH Director, Dr. Francis Collins, with additional funding from the National Institute on Aging (NIA), the lead Institute within NIH for Alzheimer’s research.
“As many as 5 million Americans face the challenge of Alzheimer’s disease, which robs them of their memories, their independence, and ultimately, their lives,” Dr. Collins said. “We are determined, even in a time of constrained fiscal resources, to capitalize on exciting scientific opportunities to advance understanding of Alzheimer’s biology and find effective therapies as quickly as possible.”
The clinical trials investigate possible ways to stop the progression of the disease. The translational research study awards are focused on identifying, characterizing and validating novel therapeutic targets.
“We know that Alzheimer’s-related brain changes take place years, even decades, before symptoms appear. That really may be the optimal window for drugs that delay progression or prevent the disease altogether,” said NIA Director Dr. Richard Hodes. “The clinical trials getting under way with these funds will test treatments in symptom-free volunteers at risk for the disease, or those in the very earliest stages—where we hope we can make the biggest difference.”
Basic and genetic studies of the disease—from the abnormal proteins involved, to genetic influences, to inflammation and other Alzheimer’s-related brain changes—have advanced our knowledge. This has given us new insights into the biological underpinnings of this extremely complex disorder, Dr. Hodes said.
Today’s awards support the following clinical trials. (Individual investigators can be contacted about when these studies will recruit participants.):
- See more at: http://www.nia.nih.gov/newsroom/2013/09/nih-funding-boosts-new-alzheimers-research-prevention-novel-drug-targets#sthash.LdFTJjkC.dpuf
No comments:
Post a Comment